topotecan has been researched along with Leukemia, Myeloid in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Animati, F; Bellarosa, D; Bigioni, M; Binaschi, M; Bressan, A; Bugianesi, R; Crea, A; Maggi, CA; Manzini, S; Parlani, M; Rivoltini, L | 1 |
| Abbott, BL; Andreeff, M; Barnes, Y; Colapietro, AM; Marini, F; Sorrentino, BP | 1 |
| Alvarez, R; Beran, M; Cortes, J; Estey, E; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, AM | 1 |
| Berger, SJ; Cooper, BW; Donaher, E; Gerson, SL; Gosky, DM; Green, SB; Hoppel, CL; Ingalls, ST; Lazarus, HM; Li, X; Rosenthal, NS | 1 |
| Estey, EH; Thall, PF | 1 |
| Cortes, JE; Douer, D; Estey, EH; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, SS; Kantarjian, HM; Koller, CA; Levine, AM; O'Brien, SM; Thomas, DA | 1 |
| Diehl, V; Hoffmann, M; Seiberlich, B; Staib, P; Tesch, H; Weihrauch, MR | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Crump, M; Hedley, DW; Nicklee, T | 1 |
| Beare, S; Crump, M; Eisenhauer, E; Hedley, D; Lipton, J; Minden, M; Shepherd, F; Stewart, K; Sutton, D | 1 |
| Beran, M; Cortes, J; Estey, E; Kantarjian, H; Koller, C; O'Brien, S; Vey, N | 1 |
| Kantarjian, H | 1 |
| Ciolli, S; Fanci, R; Leoni, F; Nozzoli, C; Rossi Ferrini , P; Santini, V | 1 |
| Chiusolo, P; Leone, G; Mazzotta, S; Mele, L; Pagano, L; Putzulu, R; Voso, MT | 1 |
1 review(s) available for topotecan and Leukemia, Myeloid
| Article | Year |
|---|---|
New developments in the treatment of acute myeloid leukemia: focus on topotecan.
Topics: Acute Disease; Antineoplastic Agents; Combined Modality Therapy; Humans; Leukemia, Myeloid; Prognosis; Topoisomerase I Inhibitors; Topotecan | 1999 |
7 trial(s) available for topotecan and Leukemia, Myeloid
| Article | Year |
|---|---|
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Topics: Acute Disease; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Gemtuzumab; Humans; Infusions, Intravenous; Leukemia, Myeloid; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Remission Induction; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 3; Survival Rate; Topotecan; Treatment Outcome | 2002 |
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Chemical and Drug Induced Liver Injury; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Gastrointestinal Diseases; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Neoplasms, Second Primary; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Topoisomerase I Inhibitors; Topotecan | 2003 |
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Topotecan; Treatment Outcome | 2003 |
Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cytarabine; Disease-Free Survival; Female; Hemoglobinometry; Humans; Leukemia, Myeloid; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Topotecan; Treatment Outcome | 2004 |
Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cohort Studies; DNA Topoisomerases, Type II; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Topotecan | 1999 |
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Topotecan; Treatment Outcome | 1999 |
The association of topotecan and cytarabine in the treatment of secondary or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Second Primary; Recurrence; Therapeutic Equivalency; Topotecan; Treatment Outcome | 2001 |
6 other study(ies) available for topotecan and Leukemia, Myeloid
| Article | Year |
|---|---|
Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dextrans; Female; Humans; Leukemia, Myeloid; Macrophages; Melanoma; Mice; Mice, Nude; Ovarian Neoplasms; Tissue Distribution; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Low levels of ABCG2 expression in adult AML blast samples.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Cells; Bone Marrow Cells; Drug Resistance, Neoplasm; Female; Fetal Blood; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Idarubicin; Infant, Newborn; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; RNA, Messenger; RNA, Neoplasm; Topotecan | 2002 |
New designs for phase 2 clinical trials.
Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome | 2003 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry.
Topics: Animals; Antibody Specificity; Camptothecin; Cell Cycle; DNA Topoisomerases, Type II; Enzyme Inhibitors; Fluorescence; Humans; Image Cytometry; Leukemia, Myeloid; Rabbits; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |
Fludarabine, cytarabine and topotecan (FLAT) as induction therapy for acute myeloid leukemia in the elderly: a preliminary report.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Topotecan; Vidarabine | 2001 |